Sign In
Buy ALDX
$1.86
+0.220 (+13.41%)
At Close: Jun 03, 2026
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Friday, August 5, 2022 to report financial results for the quarter en
Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals
02:53pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.
Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals
01:05pm, Wednesday, 13'th Jul 2022
Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
08:59am, Wednesday, 13'th Jul 2022 Benzinga
Gainers
Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.
Aldeyra's Reproxalap Hits Primary Goals In Dry Eye Disease Chamber Crossover Trial
09:03am, Tuesday, 12'th Jul 2022
Aldeyra Therapeutics Inc (NASDAQ: ALDX) achieved the primary endpoints in a crossover clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate for dry eye disea
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, July 12, 2022, at 8:00 a.m. (ET) to report
Why Aldeyra Therapeutics' Shares Are Soaring Today?
09:47am, Wednesday, 08'th Jun 2022
Aldeyra Therapeutics Inc's (NASDAQ: ALDX) Phase 3 TRANQUILITY-2 trial of reproxalap for dry eye disease has achieved the primary endpoint. Reproxalap was statistically superior to the vehicle for ea
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Wednesday, June 8, 2022, at 8:00 a.m. (ET) to provi
Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference
04:05pm, Monday, 23'rd May 2022
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today ann
Aldeyra's Dry Eye Candidate Tops Vehicle In Post-Hoc Analysis Using Computer Automated Grading In Ocular Redness
03:29pm, Wednesday, 18'th May 2022
Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported a post-hoc analysis from the completed Phase 3 TRANQUILITY dry eye chamber trial of reproxalap for dry eye disease. Using computer-automated grading
Aldeyra Therapeutics (ALDX) Q1 2022 Earnings Call Transcript
12:30am, Friday, 06'th May 2022 The Motley Fool
ALDX earnings call for the period ending March 31, 2022.
Aldeyra Therapeutics Inc. (ALDX) CEO Dr. Todd Brady on Q1 2022 Results - Earnings Call Transcript
03:49pm, Thursday, 05'th May 2022
Aldeyra Therapeutics Inc. (NASDAQ:ALDX ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Joshua Reed - Chief Financial Officer Dr. Todd Brady - Chief Executive Officer Bru
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
12:43pm, Thursday, 05'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
The�
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
11:41am, Tuesday, 29'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug
Pfizer, Inc.
Aldeyra Therapeutics (ALDX) Q4 2021 Earnings Call Transcript
11:30am, Friday, 18'th Mar 2022 The Motley Fool
ALDX earnings call for the period ending December 31, 2021.
